Skip to main content
Clinical Trials/NCT03877003
NCT03877003
Completed
Not Applicable

Plasma TMAO and Choline Levels in Individuals With Metabolic Syndrome - Comparison Between Eggs and Choline Supplement Intake

University of Connecticut2 sites in 1 country25 target enrollmentNovember 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
University of Connecticut
Enrollment
25
Locations
2
Primary Endpoint
Plasma lipids (total cholesterol, HDL cholesterol and triglycerides) in mg/dL
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The objective of this study is to determine the effects of consuming either 3 eggs per day and compare it to daily choline supplement (choline bitartrate) for a dose of approximately 400 mg/day on plasma concentrations of high density lipoprotein cholesterol (HDL-c), trimethylamine N oxide (TMAO) and plasma choline. The goal is to determine if choline given as phosphatidyl choline (from eggs) will have a more beneficial effect on plasma choline and microbiota.

Detailed Description

Epidemiological data suggests that egg intake does not increase the risk for cardiovascular disease (CVD). In fact eggs are a good source of phosphatidyl choline (PC) and choline has a number of metabolic roles including lipid metabolism, membrane structure, liver health and a neurotransmitter. Recent reports that choline may be metabolized by the intestinal microbiota into TMAO, a compound that may increase the risk for heart disease. It is not clear how much egg contribute to TMAO formation in individuals with metabolic syndrome. Therefore the objective of this study is to determine the impact of daily intake of 3 eggs versus a choline supplement on plasma TMAO and other biomarkers for CVD risk and also to assess if there are changes in microbiota with these interventions that might lead to the increases of TMAO in plasma.

Registry
clinicaltrials.gov
Start Date
November 1, 2018
End Date
June 30, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Maria Luz Fernandez

Principal Investigator

University of Connecticut

Eligibility Criteria

Inclusion Criteria

  • All genders
  • 35-70 years
  • Metabolic syndrome (based on 3 out of 5 characteristics: waist circumference \> 88 cm for women and \> 102 cm for men, plasma triglycerides \> 150 mg/dL, fasting glucose \> 100 mg/dL, blood pressure \> 135/85 and HDL \< 40 mg/dL for men and \< 50 mg/dL for women),
  • willing to consume 3 eggs per day for 4 weeks
  • willing to consume choline supplement (400 mg/day for 4 weeks)

Exclusion Criteria

  • Self-reported diaberes, cardiovascular disease, history of stroke, liver disease or cancer
  • Taking glucose lowering medications
  • Taking antibiotics in the previous 1 month
  • Triglycerides \> 500 mg/dL,
  • Cholesterol \> 240 mg/dL,
  • blood pressure \> 145/100 mm of Hg
  • Allergic to eggs or to choline

Outcomes

Primary Outcomes

Plasma lipids (total cholesterol, HDL cholesterol and triglycerides) in mg/dL

Time Frame: 1 year

They will be measured simultaneoulsy by use of an automated spectrophotometer

Plasma choline and TMAO (micromol/L)

Time Frame: 1 year

They will be measured simultaneously by use of a mass spectrophotometer

Secondary Outcomes

  • Analysis of microbiota diversity (expressed as concentrations of different microorganisms.(1 year)

Study Sites (2)

Loading locations...

Similar Trials